• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Peripheral Artery Disease
Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial
Posted inClinical Updates Wellness & Lifestyle

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

Posted by By MedXY 09/17/2025
The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.
Read More
Timing Matters: Determining the Optimal Duration of Supervised Exercise for Meaningful Improvements in Peripheral Artery Disease
Posted inClinical Updates Wellness & Lifestyle

Timing Matters: Determining the Optimal Duration of Supervised Exercise for Meaningful Improvements in Peripheral Artery Disease

Posted by By MedXY 09/08/2025
A supervised treadmill exercise program lasting over 6 weeks is essential to achieve significant walking improvements in peripheral artery disease, with peak patient-reported benefits observed at 12 weeks but diminishing by 26 weeks.
Read More
Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial
Posted inClinical Updates Wellness & Lifestyle

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

Posted by By MedXY 09/07/2025
The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or diabetes medication use.
Read More
Lipoprotein(a) as a Prognostic Indicator for Extracoronary Atherosclerotic Disease Progression: Insights from the UK Biobank
Posted inClinical Updates Wellness & Lifestyle

Lipoprotein(a) as a Prognostic Indicator for Extracoronary Atherosclerotic Disease Progression: Insights from the UK Biobank

Posted by By MedXY 09/06/2025
Elevated lipoprotein(a) levels significantly predict incident peripheral artery disease and carotid stenosis, as well as progression to major limb events, underscoring its value as a prognostic biomarker for extracoronary atherosclerotic vascular complications.
Read More
Early Warnings of Vascular Blockage: Don’t Ignore These 4 Signs in Your Hands and Feet
Posted inWellness & Lifestyle

Early Warnings of Vascular Blockage: Don’t Ignore These 4 Signs in Your Hands and Feet

Posted by By MedXY 08/23/2025
Discover the crucial early signs of vascular blockage in hands and feet, simple self-check methods, and expert insights to protect your circulatory health effectively.
Read More
Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study
Posted inClinical Updates Medical News

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

Posted by By MedXY 08/01/2025
A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.
Read More
  • Reducing Delayed Hyponatremia After Endoscopic Transsphenoidal Surgery: The Role of Postoperative Fluid Restriction
  • Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial
  • Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema
  • Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial
  • Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COVID-19 depression diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity mental health metformin Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng Trí tuệ nhân tạo type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top